June 25, 2024

Medical Trend

Medical News and Medical Resources

Five Drugs Selected as TIME’s Best Inventions of 2023

Five Drugs Selected as TIME’s Best Inventions of 2023

Innovation drives global development, and behind every technological advancement is the force of creative activities.

For over two decades, TIME Magazine has annually selected the best inventions, showcasing the most influential new products and ideas in its special issue.

The 2023 list comprises 200 best inventions (including 50 special mentions) across 22 categories, including medical products, healthcare, assistive devices, artificial intelligence, apps, and software.

Five Drugs Selected as TIME's Best Inventions of 2023

In the medical category of the 2023 list, 15 products made the cut, including five drugs and ten medical devices. The selected drugs are Arexvy, Zurzuvae, Tzield, Leqembi, and Semaglutide.

  1. Global First: Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine

Arexvy, developed by GlaxoSmithKline, is the world’s first vaccine for Respiratory Syncytial Virus (RSV). RSV, a respiratory virus, particularly affects infants and young children. While RSV often causes mild symptoms, it can be life-threatening for certain individuals, such as premature infants, immunocompromised children, the elderly, and adults with weakened immune systems. Arexvy, approved by the FDA in May, specifically targets individuals aged 60 and above, enhancing their defense against RSV-induced lung and lower respiratory tract infections.

  1. Zurzuvae: First Oral Medication for Postpartum Depression in Adults

Sage Therapeutics’ Zurzuvae (zuranolone) received FDA approval on August 4 as the first oral medication for treating postpartum depression (PPD) in adults. PPD is a severe depressive episode that typically occurs after childbirth. Unlike previous treatments administered through intravenous injection, Zurzuvae allows women to take a pill daily for 14 days, significantly alleviating postpartum depression symptoms within three days.

  1. Tzield: Groundbreaking Drug to Delay Type 1 Diabetes

Developed by Provention Bio and Sanofi, Tzield (Teplizumab) is a monoclonal antibody designed to prevent immune cells from attacking insulin-secreting beta cells in the pancreas. While conventional treatments manage type 1 diabetes, Tzield aims to slow down the progression of the disease. Despite its high cost, Tzield represents the first therapeutic approach addressing the actual cause of type 1 diabetes.

  1. Leqembi: New Drug for Early Alzheimer’s Disease

Lecanemab (Leqembi), developed by Eisai and Biogen, is an antibody infusion therapy targeting and clearing beta-amyloid proteins in the brain. FDA-approved in January 2023, Leqembi treats early-stage Alzheimer’s disease, including patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The drug reduces beta-amyloid in the brain, slowing cognitive and functional decline. Priced at approximately $26,500 per year, Leqembi marks a significant step forward in Alzheimer’s disease treatment.

  1. Semaglutide: Breakthrough Drug for Weight Loss

Semaglutide, a GLP-1 peptide drug by Novo Nordisk, is a powerhouse in 2023, showing remarkable efficacy not only in type 2 diabetes and obesity but also in clinical studies related to cardiovascular disease, chronic kidney disease, and non-alcoholic fatty liver disease.

These five drugs, recognized by TIME as the best inventions of 2023, exemplify groundbreaking advancements in medical science, offering new hope and solutions to various health challenges.

Five Drugs Selected as TIME’s Best Inventions of 2023


  • About Arexvy. Arexvy.com. Retrieved on 15.11.2023.
  • FDA Approves First Oral Treatment for Postpartum Depression. FDA.gov. 04.08.2023.
  • Lecanemab Approved for Treatment of Early Alzheimer’s Disease. Alzheimer’s Association. Retrieved on 15.11.2023.
  • THE BEST INVENTIONS OF 2023. 200 innovations changing how we live. Times. Retrieved on 15.11.2023.

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.